Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Merck & Co. has agreed to license an investigational oral small molecule lipoprotein(a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the ...

(Image Credits: Pixabay) Merck on Tuesday announced that it has signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion. The deal will give the U.S. drugmaker access to an ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best ...

Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO ...

The drug delivery company could also receive additional payments if Merck exercises its exclusive option. Allen Templeton, vice president, pharmaceutical sciences, Merck Research Laboratories, said: ...

Daily Merck & Company, Inc. Dow pharmaceutical components are leading overall index losses. Merck emerged as the biggest decliner, down 4.6%, while Amgen shed 4.3% and Johnson & Johnson lost 4.1%.

With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before. About 30% of Big Pharma ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...